newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - EUPRAXIA PHARMACEUTICALS INC

  • Explicit Guidance:

    • Financial Runway: Cash and short-term investments extend through Q3 2028.
    • Capital Requirements: Estimated incremental capital raise of $125 million required to complete Phase 3 and reach NDA submission.
    • Timeline Milestones: Interim data analysis expected "within the next several weeks" (specifically December for 60 patients to 24 weeks; first 20 patients to 52 weeks). End-of-Phase 2 meeting targeted for the first part of 2027.
    • Launch Expectation: Product launch anticipated by 2030.
  • Business-Segment Outlook:

    • Primary Indication (EOE): Launch targeting a market of 470,000 diagnosed patients (growing to 724,000 by mid-2026 and >1 million by 2030).
    • Secondary Indications (Expansion Pipeline):
      • Benign Esophageal Strictures: Targeting 500,000 US patients; a Phase 2 trial is already included in the current budget and timeline.
      • Fibrostenosis: Clinical interest from investigators in applying the platform to other fibrotic conditions; potential commercial efficiency via same GIs, injection catheter, and submucosal delivery.
    • Commercial Model: Positioned as a medical benefit (not pharmacy benefit) to capture increased procedural fees; aims to address the 45% of the market unaddressed by current therapies (PPIs and biologics).
    • Backlog/Recruitment: Fully recruited for the current Phase 2 trial; demonstrated 2x recruitment rate compared to other EOE trials.
  • Market and Competitive Outlook:

    • Demand Trends: EOE is a progressive fibrostenotic disease with steady growth (~72,000 new diagnoses/year in the US); current standard of care fails to address fibrosis reversal or long-term compliance.
    • Competitive Landscape:
      • PPIs: 60% of first-line patients progress to fibrosis despite symptom control.
      • Oral Corticosteroids: High non-compliance (70–90% long-term); intermittent use shown to be no different than placebo.
      • Biologics: Currently capture ~8% of the market; aim to grow to 25%, leaving significant share for the company's offering.
    • Differentiation: Unique value proposition in reversing fibrosis (structural improvement) and strictures, contrasting with competitors (e.g., siglede inhibitors) that reduce eosinophil counts without meaningful clinical symptom improvement.
    • Market Share Goal: Aiming to displace oral steroids and capture the unaddressed 45% of the market, alongside PPIs (30%) and biologic growth (25%).
  • Macro / Industry Outlook:

    • Regulatory Path: The disease indication is no longer orphan status (FDA acknowledgement in late 2023); targeting End-of-Phase 2 meeting in early 2027 to define registrational path.
    • Diagnostic Trends: Conservative tracking using specific diagnostic claims (K20.0) suggests patient population growth is underestimated; real-world identification is accelerating.
  • Strategic Initiatives:

    • Clinical Trials:
      • Phase 2 Part 2: Blinded, placebo-controlled (20 sham injections vs. top two doses of active) with 6-month follow-up; looking for statistical significance in endpoints (SDI, EOHSS, EREFs).
      • Protocol Amendment: Extended patient follow-up to 2 years to better determine timing for a potential second dose (ideally at 12 months).
      • Phase 3: Planned to commence after successful Phase 2 interim data and End-of-Phase 2 meeting.
    • Product Positioning: Single annual injection (zero-order kinetics for 365 days) targeting the procedural workflow of gastroenterologists (piggybacking on standard endoscopies).
    • M&A/Partnerships: None explicitly stated; focus remains on organic execution of Phase 2/3 and potential capital raise.
  • Risks and Headwinds to Outlook:

    • Clinical Endpoint Risk: Interim data is not powered for statistical significance; management expects "strong directional trends" rather than definitive statistical wins in this small cohort.
    • Safety Caveats: One patient reported oropharyngeal candidiasis (assumed active arm); ongoing monitoring for rare injection complications (perforation, abscess, etc.).
    • Execution Risk: Dependence on successful "truth teller" consistency across three endpoints (symptoms, histology, endoscopy) to validate the program for Phase 3.
    • Funding Risk: Requires ~$125 million incremental raise to fund Phase 3 to NDA.
    • Timeline Risk: Launch contingent on successful interim data, regulatory meetings, and eventual NDA approval.
  • Management Tone on the Future:

    • Confidence: High confidence in the clinical mechanism (reversal of fibrosis) and safety profile (no adrenal suppression, zero candidiasis in trial).
    • Hedging: Explicitly states interim data may not show statistical significance due to sample size and endpoint noise; frames success as "hitting out of the park" if significance is achieved.
    • Pacing: Describes the pipeline as "exciting" and the market as "remarkable," but cautions that "data will really drive" the second-dose timing and ultimate commercial strategy.
  • Miscellaneous:

    • Safety Data: Zero oropharyngeal candidiasis in the trial cohort (3,000+ injections performed); no cortisol suppression; no change in glucose.
    • Recruitment Efficiency: Recruitment rate was 2x that of any other EOE trial, indicating strong physician and patient interest.
    • Procedural Efficiency: Injection procedure adds 10 minutes or less to standard endoscopy; 5–10 seconds per injection.
Company
EUPRAXIA PHARMACEUTICALS INC
Keywords
EUPRAXIA PHARMACEUTICALS INC